Edition:
United States

Oncodesign SA (ALONC.PA)

ALONC.PA on Paris Stock Exchange

11.80EUR
6:01am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€11.80
Open
€11.89
Day's High
€11.89
Day's Low
€11.77
Volume
3,471
Avg. Vol
5,182
52-wk High
€18.14
52-wk Low
€11.11

Chart for

About

Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its... (more)

Overall

Beta: -0.56
Market Cap(Mil.): €80.46
Shares Outstanding(Mil.): 6.82
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.36 16.99
EPS (TTM): -- -- --
ROI: -- 2.41 11.25
ROE: -- 3.35 15.06

BRIEF-Oncodesign H1 net loss widens to ‍​1.9 million euros

* H1 NET LOSS EUR ‍​1.9 MILLION VERSUS LOSS OF EUR 1.8 MILLION YEAR AGO

Sep 19 2017

BRIEF-Oncodesign buys Bertin Pharma's pharmaceutical and biotech services businesses

* ONCODESIGN ANNOUNCES THE ACQUISITION OF BERTIN PHARMA’S PHARMACEUTICAL AND BIOTECH SERVICES BUSINESSES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 31 2017

BRIEF-Oncodesign report stable H1 revenue of 5.9 million euros

* ONCODESIGN HAD EUR 10.2 MILLION OF AVAILABLE CASH AT JUNE 30, 2017, AN INCREASE OF EUR 600 THOUSAND RELATIVE TO DECEMBER 31, 2016

Jul 20 2017

BRIEF-Oncodesign starts talks with Bertin Pharma for acquisition of service businesses

* ONCODESIGN OPENS EXCLUSIVE NEGOTIATIONS WITH BERTIN PHARMA FOR THE ACQUISITION OF SERVICE BUSINESSES

May 10 2017

Earnings vs. Estimates